What Zephyr AI does

Zephyr AI is a private healthcare technology company founded in 2020 that develops artificial intelligence and machine-learning systems for drug discovery, biomarker development, precision medicine, and therapeutic lifecycle decision support. It primarily serves biopharma and diagnostics companies, with research institutions as a secondary customer segment. Its offering combines the AIM Suite, which predicts therapy response and supports companion diagnostics and gene-expression reconstruction, with Nexus, a real-world intelligence platform for cohort construction, synthetic controls, and longitudinal analysis.

The underlying platform integrates clinical, genomic, digital pathology, and whole-slide image data. Zephyr AI reports access to more than 90 million patient records, including more than 1 million patients with NGS data and more than 400,000 lifetime-consented oncology patients. Named capabilities include AIM-Bx, AIM-io, AIM-CDx, AIM-Ex, ImmunoBERT, Mut2Ex, Aster Avatar, and generative Bayesian-network methods. The company reports validation in real-world cohorts and, for selected models, performance exceeding conventional biomarkers, but it does not disclose patents, regulatory clearances, or scaled commercial clinical deployments.

Zephyr AI sells through direct enterprise partnerships rather than self-serve distribution. Revenue is generated through platform access, partner-specific model fine-tuning, pilots and proof-of-concept studies, full development programs, and companion-diagnostic co-development, with custom pricing based on scope. Its go-to-market is consultative and evidence-led, using scientific conferences and enterprise relationships to reach biopharma and diagnostics organizations; public pricing, contract values, customer counts, and revenue are not available.

Name

Zephyr AI

Legal name

Zephyr AI, Inc.

Website

https://zephyrai.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Zephyr AI develops multimodal AI and real-world data tools for biopharma and diagnostics companies, supporting treatment-response prediction, biomarker discovery, patient stratification, and companion-diagnostic development across therapeutic lifecycles through its AIM Suite and Nexus platform.

Ownership category

akta.pro rank

Product category

AI Precision Medicine Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Precision medicine AI
• Drug discovery platform
• Companion diagnostics development
• Real-world data analytics
• Biomarker prediction models

Headquarters

HQ city

Fairfax Station

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Platform Licensing & Partnerships: Zephyr AI generates revenue through partnerships with biopharma and diagnostics companies, providing access to their multi-modal AI platform and real-world data assets. Revenue comes from platform access fees, fine-tuning AI models for partner-specific drugs and assays, and co-development programs for companion diagnostics. The company supports pilots, proof-of-concept studies, and full development programs with custom pricing based on scope.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Zephyr AI builds and licenses the AIM Suite, a multi-modal AI platform that combines clinical, genomic, digital pathology, and EHR/claims data from 90M+ patients to predict treatment response, stratify patients for trials, and co-develop companion diagnostics with biopharma and diagnostics partners. Offerings include AIM-Bx (predictive biomarker), AIM-io (immune checkpoint inhibitor response prediction), AIM-CDx (companion diagnostics co-development), AIM-Ex (mRNA expression reconstruction), and Nexus (real-world intelligence and analytics platform). The platform is delivered through enterprise partnerships, pilots, and full co-development programs with custom pricing.

Product overview

Zephyr AI is a precision medicine technology company offering a multi-modal AI platform called the AIM Suite, consisting of modular, biologically interpretable AI tools designed for seamless integration into R&D workflows. The platform is built on enterprise-scale real-world data spanning 90M+ patients (including 1M+ with NGS and 400K+ lifetime-consented oncology patients from Aster Insights and ORIEN/TCC). The AIM Suite includes AIM-Bx (predictive biomarker for small molecules), AIM-io (immune checkpoint inhibitor response prediction), AIM-CDx (companion diagnostics co-development), and AIM-Ex (mRNA expression reconstruction from DNA-based LDTs). Nexus provides real-world data analytics, cohort construction, and synthetic controls. The platform integrates multi-modal data (clinical, genomic, digital pathology, whole-slide imaging) and has been validated across diverse real-world patient cohorts.

Differentiator

Problem solved

Functional benefit

Products and services

• AIM-Bx Multi-modal AI biomarker platform predicting response to small molecule therapies using clinically available data, validated in real-world cohorts and adaptable as an AI-CDx for partner drugs. Applied to KRAS inhibitors (sotorasib) and osimertinib in NSCLC.
• AIM-io Multi-modal AI model predicting response to immune checkpoint inhibitors using routine clinical inputs and whole-slide images, validated across tissue-derived data, liquid biopsy, and whole-slide image datasets with explainable tumor biology and combination therapy insights.
• AIM-CDx Companion diagnostics co-developed with biopharma and diagnostics partners, built on AIM-Bx and adapted to partner assays and assets with preclinical or clinical data for regulatory-grade companion diagnostic development.
• AIM-Ex Reconstructs mRNA expression from DNA-based LDTs and minimal clinical data with high concordance to RNAseq, enhancing interpretability of sparse tumor data and feeding downstream predictive models with biologically rich expression-level inputs.
• Nexus Real-world intelligence platform linking EHR, claims, genomics, and pathology data for discovery, validation, and market strategy. Provides analytics and insights across 90M+ patients, cohort construction, synthetic controls, AI/ML modeling, and intervention-specific risk modeling.
• Aster Avatar Matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates from Aster Insights, ideal for translational research and biomarker discovery across 400K+ lifetime-consented oncology patients.

Quantifiable outcome

• Improved prediction of survival outcomes compared to conventional biomarkers in immune checkpoint inhibitor response prediction
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Partnerships

Three partnerships are on record, tiered core.

• Guardant HealthcoreStrategic or Co-development Partner · 27 October 2025Strategic partnership to combine Guardant Health's multimodal molecular data platform with Zephyr AI's AI and machine learning technologies to discover novel cancer biomarkers for drug development, targeted therapy selection, and response monitoring. The collaboration aims to accelerate precision oncology research through integrated data science capabilities.
• Aster InsightscoreOthers · 29 August 2025Zephyr AI acquired Aster Insights, a provider of scientific and clinical intelligence, to enhance its data assets for cancer research and personalized medicine. The acquisition grants access to large longitudinal datasets from over 400,000 patients, strengthening drug development and clinical trial capabilities through the Aster Avatar matched clinical, exome, transcriptome, and digital pathology data.
• ORIEN (Oncology Research Information Exchange Network)coreTechnology or IntegrationPartnership providing access to the ORIEN Total Cancer Care study data through the 400K+ lifetime-consented oncology patients, enabling discovery and validation at scale through linked longitudinal data.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Owkin: Owkin applies AI to multi-modal patient data for biopharma drug discovery, clinical trial optimization, and diagnostics development across oncology and other therapeutic areas. Directly comparable business model combining federated learning on real-world data with biopharma partnerships and companion diagnostic ambitions.
• Tempus AI: Tempus AI is the most direct competitor, operating an AI-enabled precision medicine platform built on multi-modal clinical and molecular data (including NGS, pathology, and imaging) with biopharma and provider customers. Overlaps directly with Zephyr's AIM Suite and Nexus platform across biomarker discovery, companion diagnostics, and clinical trial enablement.
• Personalis: Personalis provides genomic profiling and molecular diagnostics for oncology, including immuno-oncology biomarker products (ImmunoID NeXT). Directly comparable in clinicogenomic data depth, oncology focus, and biopharma partnership model for biomarker and CDx development.
• Recursion Pharmaceuticals: Recursion uses AI/ML combined with high-throughput experimental biology for drug discovery, with partnerships across multiple therapeutic areas including oncology. Overlaps with Zephyr in the AI-driven drug discovery value proposition, though Recursion focuses more on internal pipeline and target identification while Zephyr focuses on biomarker and patient stratification.
• PathAI: PathAI applies AI to digital pathology for biomarker discovery, companion diagnostics, and biopharma services, with strong overlap on the AIM-io whole-slide image modality and pathology-driven biomarker work. Comparable biopharma partnership model and disease-area focus in oncology.
• Schrödinger: Schrödinger operates a computational chemistry and AI-driven drug discovery platform serving biopharma partners through licensing and co-development. Overlaps with Zephyr on the AI-for-drug-discovery positioning and biopharma enterprise GTM, though focused on molecular simulation rather than multi-modal patient data.

Broad incumbents

• Guardant Health: Guardant Health is a leading liquid biopsy and genomics company with established diagnostic products (Guardant360, Guardant Reveal) and extensive clinicogenomic data assets. Now both a strategic partner to Zephyr and a broad incumbent in the oncology precision medicine space where Zephyr's biomarkers compete.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) is an established leader in comprehensive genomic profiling and companion diagnostics for oncology. Represents a broad incumbent competitor with deeper commercial reach into oncology drug developers and FDA-approved CDx products.

Emerging players

• Verge Genomics: Verge Genomics uses AI on human patient data sets to discover and develop drugs for neurological diseases. Overlaps on the AI + real-world patient data + biopharma value proposition, with a different therapeutic focus (neurodegeneration) and emerging-stage pipeline.
• Deep Genomics: Deep Genomics applies AI to identify novel drug targets and develop oligonucleotide therapies, focused on genetic diseases. Shares the AI-for-drug-discovery positioning but operates with a different therapeutic focus and earlier-stage therapeutic pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/zephyr_ai
• LinkedInlinkedin.com/company/zephyr-ai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zephyr AI